- Home
- Companies
- saudi arabia
- therapeutic antibody development
Show results for
Refine by
Therapeutic Antibody Development Suppliers Serving Saudi Arabia
49 companies found
based inArcugnano (VI), ITALY
Since 1983 we have been working to become the international landmark in lasertherapy and magnetotherapy for multidisciplinary use: from physiotherapy to rehabilitation, from pain management – both muscular and articular - to sports medicine and ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inWaltham, MASSACHUSETTS (USA)
Kalaris was founded by experienced leaders in ophthalmology drug development and commercialization to address a major unmet need in the treatment of retinal diseases. Existing therapies for retinal neovascular / exudative diseases have made great ...
Kalaris Therapeutics is focused on developing innovative treatments for retinal diseases, aiming to reduce the burden of frequent clinical visits for patients with retinal neovascular and exudative conditions. Their lead product, TH103, is a fully ...
based inEmeryville, CALIFORNIA (USA)
Nutcracker Therapeutics is an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designed to enable the advancement of RNA-based treatments for as many diseases as possible, as fast as possible. ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
based inVienna, AUSTRIA
Aposcience AG is a worldwide innovation leader in the field of regenerative medicine. Regenerative medicine has the potential to transform the treatment for diseases with high medical need, as the tissues afflicted by the disease process can be ...
based inFlagstaff, ARIZONA (USA)
Symple Surgical is an exciting start-up Medical Device company focused on developing novel therapeutic technologies through controlled Microwave Ablation. Our technologies are thoughtfully designed to be familiar and easy to use by the operator ...
based inHeidelberg, GERMANY
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to ...
based inWaltham, MASSACHUSETTS (USA)
Third Pole Therapeutics develops and delivers critical life-sustaining cardio-pulmonary therapies. Warren Zapol, M.D., Third Pole’s founder, invented the first use for inhaled nitric oxide (iNO) for the treatment of hypoxic respiratory failure in ...
based inAustin, TEXAS (USA)
Direct Biologics is a leader in regenerative medicine, focusing on the development of next-generation bioactive products derived from stem cells. Their innovative technology centers on Extracellular Vesicle (EV) products, which are formulated from ...
based inAlexandria, VIRGINIA (USA)
The American Statistical Association is the world’s largest community of statisticians, the “Big Tent for Statistics.” It is the second-oldest, continuously operating professional association in the country. Since it was founded in Boston in 1839, ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal ...
based inPozuelo de Alarcón, SPAIN
We are a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Our operations encompass the marketing of both our own and licensed products and the provision of services, such ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inOverath, GERMANY
Spiggle & Theis Medizintechnik GmbH was founded as a family-owned company in 1994 in Dieburg near Darmstadt. Since then, SPIGGLE & THEIS has been developing and distributing its products in over 75 countries worldwide. By keeping an eye on the ...
based inBalerna, SWITZERLAND
APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
